Cue Biopharma
Kristin Y. has worked in a variety of roles in the scientific field since 2005. Starting in 2005, they were an Engineering Aide for the United States Army. In 2008, they worked as a Research Assistant at the University of the Sciences in Philadelphia in the Department of Pharmacology and Toxicology, where they investigated protective effects of taurine. In 2010, they were a Temporary Research Associate at Adnexus Therapeutics, a BMS Research and Development Company. In 2011, they moved to Bristol-Myers Squibb where they were an Associate Research Scientist I. In 2015, they moved to Alnylam Pharmaceuticals as a Senior Associate Scientist. Most recently, they have been at Cue Biopharma since 2018, where they have held the roles of Senior Scientist, Scientist, and Senior Associate Scientist.
Kristin Y. received their B.S. in Pharmacology and Toxicology from the University of the Sciences in Philadelphia in 2010. Kristin then pursued a Master's degree in Biotechnology Management from Harvard University Extension School, which they completed in 2017.
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.